|
Originally published In Press as doi:10.1074/jbc.M102542200 on July 6, 2001
J. Biol. Chem., Vol. 276, Issue 39, 36695-36702, September 28, 2001
Glucose-induced Toxicity in Insulin-producing
Pituitary Cells That Coexpress GLUT2 and Glucokinase
IMPLICATIONS FOR METABOLIC ENGINEERING*
Raquel N.
Faradji §,
Evis
Havari ,
Qian
Chen ,
John
Gray ,
Keith
Tornheim**,
Barbara E.
Corkey**,
Richard C.
Mulligan , and
Myra A.
Lipes 
From the Joslin Diabetes Center, Department of
Medicine, Harvard Medical School, Boston, Massachusetts 02215, the
** Department of Biochemistry and the Obesity Research
Center, Boston University Medical Center, Boston, Massachusetts
02118, and the Howard Hughes Medical Institute, Children's
Hospital, Harvard Medical School, Boston, Massachusetts
02215
We have shown that intermediate lobe (IL)
pituitary cells can be engineered to produce sufficient amounts of
insulin (ins) to cure diabetes in nonobese diabetic mice but,
unlike transplanted islets, ILins cells evade immune attack. To confer
glucose-sensing capabilities into these cells, they were further
modified with recombinant adenoviruses to express high levels of GLUT2
and the -cell isoform of glucokinase (GK). Although expression of
GLUT2 alone had negligible effects on glucose usage and lactate
production, expression of GK alone resulted in ~2-fold increase in
glycolytic flux within the physiological (3-20 mM)
glucose range. GLUT2/GK coexpression further increased glycolytic flux
at 20 mM glucose but disproportionately increased flux at 3 mM glucose. Despite enhanced glycolytic fluxes,
GLUT2/GK-coexpressing cells showed glucose dose-dependent
accumulation of hexose phosphates, depletion of intracellular
ATP, and severe apoptotic cell death. These studies demonstrate that
glucose-sensing properties can be introduced into non-islet cells by
the single expression of GK and that glucose responsiveness can be
augmented by the coexpression of GLUT2. However, in the metabolic
engineering of surrogate cells, it is critical that the levels of
the components be closely optimized to ensure their physiological
function and to avoid the deleterious consequences of glucose-induced toxicity.
*
This work was supported in part by the American Diabetes
Association (to M. A. L.), by National Institutes of Health Grants DK35914 (to B. E. C.), DK53064 (to K. T.), and DK53281 (to
M. A. L.), by the Howard Hughes Medical Institute (to R. C. M. and J. G.), and by the Juvenile Diabetes Research Foundation (JDRF) Center for Islet Transplantation at Harvard Medical School.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Recipient of a Mentor-Based JDRF Postdoctoral Research Award
(to M. A. L.).

To whom correspondence should be addressed: Joslin Diabetes
Center, One Joslin Place, Rm. 495, Boston, MA 02215. Tel.:
617-732-2624; Fax: 617-732-2497; E-mail:
myra.lipes@joslin.harvard.edu.
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
K K Sidhu, R C Fowkes, R H Skelly, and J M Burrin
Exogenous expression of glucagon-like peptide 1 receptor and human insulin in AtT-20 corticotrophs confers cAMP-mediated gene transcription and insulin secretion
J. Endocrinol.,
December 1, 2005;
187(3):
419 - 427.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W.-H. Kim, J. W. Lee, Y. H. Suh, S. H. Hong, J. S. Choi, J. H. Lim, J. H. Song, B. Gao, and M. H. Jung
Exposure to Chronic High Glucose Induces {beta}-Cell Apoptosis Through Decreased Interaction of Glucokinase With Mitochondria: Downregulation of Glucokinase in Pancreatic {beta}-Cells
Diabetes,
September 1, 2005;
54(9):
2602 - 2611.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-C. Lu, C. Sternini, E. Rozengurt, and E. Zhukova
Release of Transgenic Human Insulin from Gastric G Cells: A Novel Approach for the Amelioration of Diabetes
Endocrinology,
June 1, 2005;
146(6):
2610 - 2619.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.-i. Kim and Y.-h. Ahn
Role of Peroxisome Proliferator-Activated Receptor-{gamma} in the Glucose-Sensing Apparatus of Liver and {beta}-Cells
Diabetes,
February 1, 2004;
53(90001):
S60 - 65.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
H.-i. Kim, J.-Y. Cha, S.-Y. Kim, J.-w. Kim, K. J. Roh, J.-K. Seong, N. T. Lee, K.-Y. Choi, K.-S. Kim, and Y.-h. Ahn
Peroxisomal Proliferator-Activated Receptor-{gamma} Upregulates Glucokinase Gene Expression in {beta}-Cells
Diabetes,
March 1, 2002;
51(3):
676 - 685.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|